231 related articles for article (PubMed ID: 14697903)
1. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
Castagnoli K; Murugesan T
Neurotoxicology; 2004 Jan; 25(1-2):279-91. PubMed ID: 14697903
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
Khalil AA; Davies B; Castagnoli N
Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
[TBL] [Abstract][Full Text] [Related]
3. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of monoamine oxidase B in the brains of smokers.
Fowler JS; Volkow ND; Wang GJ; Pappas N; Logan J; MacGregor R; Alexoff D; Shea C; Schlyer D; Wolf AP; Warner D; Zezulkova I; Cilento R
Nature; 1996 Feb; 379(6567):733-6. PubMed ID: 8602220
[TBL] [Abstract][Full Text] [Related]
7. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
8. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.
Herraiz T; Chaparro C
Biochem Biophys Res Commun; 2005 Jan; 326(2):378-86. PubMed ID: 15582589
[TBL] [Abstract][Full Text] [Related]
9. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction.
van Amsterdam J; Talhout R; Vleeming W; Opperhuizen A
Life Sci; 2006 Oct; 79(21):1969-73. PubMed ID: 16884739
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Rajeswari A; Sabesan M
Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
[TBL] [Abstract][Full Text] [Related]
11. [Tobacco--once a medicinal plant. Does it contain substances with medicinal properties?].
Budzianowski J
Przegl Lek; 2013; 70(10):865-8. PubMed ID: 24501813
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type.
Lewis AJ; Truman P; Hosking MR; Miller JH
Tob Control; 2012 Jan; 21(1):39-43. PubMed ID: 21636610
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents.
Herraiz T
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):810-7. PubMed ID: 21992679
[TBL] [Abstract][Full Text] [Related]
17. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
18. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Naoi M; Maruyama W; Inaba-Hasegawa K; Akao Y
Int Rev Neurobiol; 2011; 100():85-106. PubMed ID: 21971004
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration.
Castagnoli K; Petzer JB; Steyn SJ; van der Schyf CJ; Castagnoli N
Inflammopharmacology; 2003; 11(2):183-8. PubMed ID: 15035820
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
